Resolve Nanotherapeutics
Nanotechnology Research • 
2665 East Mall, Vancouver, Canada • 1-10 Employees
Company overview
| Headquarters | 2665 East Mall, Vancouver, Canada |
| Website | |
| NAICS | 541713 |
| Employees | 1-10 |
Key Contact at Resolve Nanotherapeutics
Cedric Brimacombe
Co-Founder, Vice President of Business Development
Resolve Nanotherapeutics Email Formats
Resolve Nanotherapeutics uses 1 email format. The most common is {first name}{last name} (e.g., johndoe@resolventx.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@resolventx.com | 100% |
About Resolve Nanotherapeutics
We are developing the next generation of acute infection therapeutics. These will be first-in-class broad spectrum non-antibiotic therapeutics. Our drug drug targets are derived from strong clinical data and are delivered using clinically validated lipid nanoparticle RNA systems to well established target cell types. Our target indications include pneumonia, sepsis, and other conditions where endotoxin enters the blood and causes uncontrolled inflammation.
Resolve Nanotherapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Nanotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Resolve Nanotherapeutics has never raised funding before.
United States
Australia
Germany
Frequently asked questions
4.8
40,000 users
